NCD190.24

 

DIGOXIN THERAPEUTIC DRUG ASSAY

 

Effective Date of this Version

1/1/2003

 

Benefit Category

• Diagnostic Laboratory Tests.

• Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

 

Item/Service Description

• A digoxin therapeutic drug assay is useful for diagnosis and prevention of digoxin toxicity, and/or prevention for under dosage of digoxin.

 

Indications and Limitations of Coverage

 

Indications

• Digoxin levels may be performed to monitor drug levels of individuals receiving digoxin therapy because the margin of safety between side effects and toxicity is narrow or because the blood level may not be high enough to achieve the desired clinical effect.

• Clinical indications may include individuals on digoxin:

o With symptoms, signs or electrocardiogram (ECG) suggestive of digoxin toxicity.

o Taking medications that influence absorption, bioavailability, distribution, and/or elimination of digoxin.

o With impaired renal, hepatic, gastrointestinal, or thyroid function.

o With pH and/or electrolyte abnormalities.

o With unstable cardiovascular status, including myocarditis.

o Requiring monitoring of patient compliance.

• Clinical indications may include individuals:

o Suspected of accidental or intended overdose.

o Who have an acceptable cardiac diagnosis (as listed) and for whom an accurate history of use of digoxin is unobtainable.

• The value of obtaining regular serum digoxin levels is uncertain, but it may be reasonable to check levels once yearly after a steady state is achieved.

o In addition, it may be reasonable to check the level if:

 Heart failure status worsens.

 Renal function deteriorates.

 Additional medications are added that could affect the digoxin level.

 Signs or symptoms of toxicity develop.

• Steady state will be reached in approximately 1 week in patients with normal renal function, although 2-3 weeks may be needed in patients with renal impairment.

o After changes in dosages or the addition of a medication that could affect the digoxin level, it is reasonable to check the digoxin level one week after the change or addition.

o Based on the clinical situation, in cases of digoxin toxicity, testing may need to be done more than once a week.

• Digoxin is indicated for the treatment of patients with heart failure due to systolic dysfunction and for reduction of the ventricular response in patients with atrial fibrillation or flutter.

o Digoxin may also be indicated for the treatment of other supraventricular arrhythmias, particularly in the presence of heart failure.

 

Limitations

• This test is not appropriate for patients on digitoxin or treated with digoxin FAB (fragment antigen binding) antibody.

• Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

 

Cross Reference

• Also see the Medicare Claims Processing Manual, Chapter 120, Clinical Laboratory Services Based on Negotiated Rulemaking.

 

Coverage Transmittal Link

• http://www.cms.gov/transmittals/downloads/r17ncd.pdf

 

Other

Covered Code Lists (including narrative)

• January 2013

October 2012

July 2012

April 2012

January 2012

October 2011

July 2011

April 2011

January 2011

October 2010

July 2010

April 2010

January 2010

October 2009

July 2009

April 2009

January 2009

October 2008

July 2008

April 2007

January 2007

 

Changes to Lab NCD Edit Software

• January 2012

October 2011

January 2011

October 2010

July 2010

October 2009

July 2009

January 2009

October 2008

July 2008

April 2007

January 2007

October 2006

July 2006

April 2006

January 2006

October 2005

July 2005

April 2005

January 2005

October 2004

July 2004

April 2004

January 2004

October 2003

July 2003

April 2003

 

 

Medicare NCD Link